The Centre for Drug Research and Development has spun out the company to develop a rapid detection test based on the body's immune response.
Executives of firms developing and launching various assays believe their diagnostic tests will be among the most important tools in controlling Zika.
Researchers from the diagnostics company will work with researchers from the microbial genomics lab of George Weinstock.
The company is also developing a next-generation sequencing product that may be applied at the point of need to test for bloodstream infections and later as a liquid biopsy for cancer.
